Pfizer v GlaxoSmithKline Biologicals (CFI, 3 December 2024)
| Date | 3 December 2024 |
|---|---|
| Court | CFI |
| Division | Milan (IT) Central Division- Section |
| Type of action | Preliminary objection |
| Registry reference | App_56246/2024 · ORD_58802/2024 |
| Parties | Pfizer Manufacturing Belgium S.A, Pfizer Inc, Pfizer Europe MA EEIG, Pfizer S.A, Pfizer Ltd, Pfizer Pharma GmbH, Pfizer Service Company S.R… |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 2 December 2024 (UPC_CFI_476/2024, ACT_45928/2024, ORD_58802/2024), the Milan Central Division dismissed GlaxoSmithKline Biologicals’ preliminary objection to Pfizer’s revocation action against EP 4 183 412. The order clarifies two conditions of Art. 33(4) UPCA: identity of parties is assessed entity by entity, and the earlier infringement action must concern a patent already granted.
Question
Does an infringement action brought before the Düsseldorf Local Division before the mention of grant deprive the Central Division of competence over the revocation action, where two of the claimants are not defendants there?
Decision
« The same parties » requires identity of parties, each legal entity being considered individually. Membership of the same group is not enough, and the overlap here is only partial. Moreover, a patent is granted on the date the mention of grant is published in the European Patent Bulletin (14 August 2024), the Düsseldorf action, lodged on 5 August 2024, therefore appears inadmissible when brought and cannot defeat the Central Division’s competence. The objection does not stay the proceedings (Rule 19.6), no hearing was needed and the auxiliary request for a stay was refused. Leave to appeal was granted.
Key points for practice
- Practical point: an infringement action lodged before the mention of grant does not lock competence in favour of the local division seised, and the Central Division remains competent as regards entities that are not parties to it.
Provisions applied
- Agreement on a Unified Patent Court
- Arts. 2(e) to (g), 32(1)(a), 33(4) and 73(2)(b)
- Rules of Procedure
- Rules 19, 220.2, 264, 271.6(b) and 295(m)
- European Patent Convention
- Art. 64(1), Art. 97(3)
- Regulation (EU) No 1257/2012
- Art. 4(1)
- Case law cited
- Edwards Lifesciences v Meril Italy, Paris Central Division, 13 November 2023, Amgen v Sanofi-Aventis Deutschland, Munich Central Division, 24 August 2023, Seoul Viosys v Laser Components, Paris Local Division, 24 July 2024, Tesla v Avago, Munich Local Division, 25 August 2023
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: Local and central divisions (UPC).
Dhenne Avocats blog: The Transitional Period and the UPC: Coordinating Two Judicial Orders.
Publications by Matthieu Dhenne: Pleading the Long Arm: What a UPC Statement of Claim Must Carry Beyond Jurisdiction, Valeo v. Bosch and the Redistribution of Cases Within the UPC (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- claimantPfizer Europe MA EEIG2 decisions in the corpusFollow this party
- claimantPfizer Manufacturing Belgium S.A.2 decisions in the corpusFollow this party
- claimantPfizer Ltd.2 decisions in the corpusFollow this party
- claimantPfizer Inc.7 decisions in the corpusFollow this party
- claimantPfizer S.A.3 decisions in the corpusFollow this party
- claimantPfizer Pharma GmbH2 decisions in the corpusFollow this party
- claimantPfizer Service Company S.RFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Preliminary objection
- Outcome (Dhenne Avocats summary)
- L'exception préliminaire est rejetée : l'identité de parties de l'art. 33, paragraphe 4, s'apprécie entité par entité, et une action en contrefaçon introduite avant la mention de la délivrance ne fait pas obstacle à la compétence de la division centrale.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 4 183 412mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Seoul Viosys v Laser Components (CFI, 24 July 2024) cited in this record
- Edwards Lifesciences v Meril Italy (CFI, 13 November 2023) cited in this record
- Avago Technologies International Sales v Tesla Germany (CFI, 25 August 2023) cited in this record
- Amgen v Sanofi-Aventis Deutschland (CFI, 24 August 2023) cited in this record
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 4 183 412 | Mentioned in the analysis (role not qualified) Also mentioned in 4 other decision(s): Pfizer v GlaxoSmithKline Biologicals (CFI, ORD_18700/2025, 22 April 20 · Pfizer v GlaxoSmithKline Biologicals (CFI, ORD_18810/2025, 22 April 20 · GlaxoSmithKline Biologicals v Pfizer Europe MA EEIG (CFI, 11 April 202 · GlaxoSmithKline Biologicals v Pfizer Europe MA EEIG (CFI, 4 March 2025 | not recorded | not recorded | not recorded | Espacenet links not checked mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.